Status:
COMPLETED
Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.
Lead Sponsor:
Damanhour University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
20-75 years
Phase:
NA
Brief Summary
This study aims to determine the predictive effect of ATG10 and IL6 genetic polymorphisms in safety and efficacy of sorafenib used for the treatment of Egyptian HCC patients. Moreover, this study will...
Detailed Description
A prospective pharmcogentic study for Egyptian HCC patients treating with oral sorafenib. 1. Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy, Damanhour University. 2. ...
Eligibility Criteria
Inclusion
- A diagnosed HCC patient.
- Child-pugh class A.
- Performance status 1-2 (ECOG scale)
- Laboratory investigation : Hemoglobin ≥8.5 mg\\dl, INR ≤2.3 ,Albumin≥2.8g\\dl, ALT and AST ≤ 3 times the ULN
- Age ≥20 years.
Exclusion
- Patients refused to sign the written consent.
- Age \> 75 years.
- Renal failure requiring hemo- or peritoneal dialysis
- History of cardiac disease
- Active clinically serious infections
- Known history of human immunodeficiency virus (HIV) infection
- Pregnant female
- Child-pugh class B and C.
- Performance status 3 or 4.
- Patient who are indicated for surgical resection or liver transplant (MDT).
Key Trial Info
Start Date :
December 12 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06030895
Start Date
December 12 2022
End Date
March 1 2024
Last Update
March 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University Hospital
Al Mansurah, El-Dakahelia, Egypt, 31527